《跨国医药企业合作模式.pdf》由会员分享，可在线阅读，更多相关《跨国医药企业合作模式.pdf（4页珍藏版）》请在taowenge.com淘文阁网|工程机械CAD图纸|机械工程制图|CAD装配图下载|SolidWorks_CaTia_CAD_UG_PROE_设计图分享下载上搜索。
1、Power in PartnershipsTurning Ideas Into Reality Through R 2008 Eli Lilly and Company.All Rights Reserved.Information about Data Privacy at Lilly can be found at: Lilly,we recognize the important role that relationships play in generating innovation andhelping achieve our common goal:improving the li
2、ves of individual patients around the world.Weve developed a variety of networks to generate ideas,access new resources,and delivereffective therapies to patients who need them.One of our growing networks is the Lilly Alumni Network(LAN).Through LAN,former colleaguesare able to renew relationships,e
3、xplore business opportunities,and track developments at Lillyand beyond.To register,visit or call 888-LLY-ALUM.“Lillys number-one priority is increasing the flow of innovativeproducts that make a realdifference for patients.Partnering has been a key element of our strategyfor more than a decade,and
4、successful partner-ships are essential forLillys ongoing pursuit of innovation.”John Lechleiter,Ph.D.President andChief Executive OfficerEli Lilly and CompanyWere Committed to Sharing Success Almost a century ago,an alliance partner helped us producethe worlds first commercial insulin product.Anothe
5、r partnerworked with us to bring the world its first human healthbiotech product human insulin.We were the first in our industry to establish an office ofalliance management.Our more than 100 active alliance partnerships run the gamutfrom discovery,to development,to commercialization.Partnerships ar
6、e a key component of our strategy for the future.We are committed to innovation and the success of our partnerships.Lilly at a GlanceWith a heritage more than 130 years strong,Lilly was founded on May 10,1876.Approximately 8,000 employees are engaged in research and development.R&D as a percentage o
7、f sales was 19 percent in 2007.Clinical research conducted in more than 50 countries.Research and development facilities are located in 9 countries.Manufacturing plants are located in 13 countries.Lilly is recognized as having an award-winning culture:FORTUNE magazine“Global Most Admired Companies”M
8、ONEY magazine“Americas Best Company Benefits”Science magazine“Best Companies for Scientists”IndustryWeek“100 Best-Managed Companies”Business Ethics magazine“100 Best Corporate Citizens”FORTUNE magazine“50 Best Companies for Minorities”ProteinPeptideAntibodyAntisenseSmall MoleculeLarge MoleculeTherap
9、eutic ModalitiesEli Lilly and CompanyLilly Research LaboratoriesOncology Targeted cancer therapies Novel predictive biomarkers Drug formulations and com-binations that provide clearmedical benefit advantagesand differentiationNeuroscience Innovative clinical and pre-clinical approaches relatedto Psy
10、chiatry,Neurology aswell as pain and migraine Novel predictive biomarkersCardiovascular Innovative clinical and pre-clinical approaches focusedin atherosclerosis,metabolicsyndrome,coronaryischemia,and hypertension Novel predictive biomarkersEndocrinology Innovative approaches,including targets,for t
11、ype 1 and 2 diabetes and obesity Novel insulin approaches Novel biomarkers for meas-urement of beta cell massand function as well as efficacy assessment of anti-obesity treatmentsMusculoskeletal Novel clinical and preclinicaltherapies for the treatmentof osteoporosis,frailty,and arthritis Novel drug
12、gable targets for the treatment of osteoporosis,osteoarthritis,and muscle loss/frailty Novel predictive biomarkersOther areas of interest Inflammatory/auto-immune diseases Key womens health issues Anemia IBS Areas of high unmet medical needTechnologies driving development across the R&D value chain
13、Chemistry Informatics Pharmacology Biomarkers Drug deliveryWhile Lilly has excelled in small molecule therapeutics,our effort in large molecules has grownin recent years.Biotechnology is far from new for Lilly.Insulin the drug that helped firmly establishLilly was a biotech discovery.Lillys current
14、product portfolio boasts other biotech molecules,including Forteo,Byetta,and Xigris.In 2007,Lilly had$4.56 billion in sales of biotherapeutics.Additionally,biotherapeutics represent approximately one-third of our pipeline.Today,Lilly has a unique and powerful combination of small-and large-molecule
15、drug discoveryplus deep therapeutic area medical expertise.In the Pursuit of InnovationOur mission:to discover,develop,and commercialize innovative pharmaceutical therapies thatenable people to live longer,healthier,and more active lives.Lilly Research Laboratories focuses R&D efforts across a diver
16、se set of therapeutic platforms.Our areas of interest focus mainly on first-in-class or best-in-class medicines.Lillys Global PresenceResearchManufacturingSales OfficeTransforming Lillys Business ModelThis is an important collaboration for Lilly inthe field of osteoporosis,and leverages our owninter
17、nal expertise withEvista,Forteo,andarzoxifene.The targetsthat Galapagos has discovered provide anexcellent basis for thepotential development of innovative drugs withbone-forming properties.William W.Chin,M.D.Vice President,Discovery Research and Clinical InvestigationEli Lilly and CompanyRewarding
18、SuccessLilly and Belgium-based Galapagos have partnered tocapitalize on their complementary expertise in thefield of osteoporosis.Galapagos is prosecuting 12osteoporosis drug discovery programs from the targetstage through proof of concept.The benefit for Galapagos:Risk-sharing partnership with big
19、pharma allows for development of novel osteoporosis therapies Clearly defined critical success factors and“success payments”via a series of early milestones Opportunity to generate downstream clinical milestones and royalty payments on global salesThe benefit for Lilly:Shared risk in the beginning s
20、tages of drug discovery Opportunity to take a global development and commercial-ization license to the compounds FIPCo:Fully Integrated Pharmaceutical Company Hub-and-spoke model based in Indianapolis Centralized governance/management Indianapolis-based fundingShared Risk and RewardLilly and Piramal
21、 Life Sciences are speeding up the drug discovery process through an agreement thatleverages both companies unique strengths.India-based Piramal Life Sciences is overseeing R&D of selected molecules from Lillys pipeline,fromdevelopment through the end of Phase II.The benefit for Piramal Life Science
22、s:Opportunity to demonstrate to pharmaceutical industry their R&D and biotech capabilities Ability to design and execute a global clinical development program Access to R&D assets which may not have otherwise been available Guaranteed milestone payments and a royalty if a product reaches the marketT
23、he benefit for Lilly:Increased productivity in drug development Access to diverse population in South Asia Option to acquire molecules for the Lilly portfolio“We believe PLSL has the strategic interest andcapabilities to advancethese Lilly moleculesthrough early clinicaldevelopment,and we are excite
24、d to explore thisinnovative drug develop-ment model with them.”Robert Armstrong,Ph.D.Vice President,Global ExternalResearch and DevelopmentEli Lilly and CompanyFIPNet:Fully Integrated Pharmaceutical Network Network of cross-functional portfolio molecules in multiple deal structures More decentralize
25、d governance/management Shared risk/reward opportunitiesIt is a virtual world today and research is no different.Lilly pursues innovation and research outsideour walls as much as we do inside our own laboratories.Were transforming from a fully-integratedpharmaceutical companythe old“FIPCo”modelinto
26、what we refer to as a fully-integrated pharmaceutical networkor“FIPNet.”As Lilly transforms,so do our partnerships.In fact,some of our partnerships are quite novel,not onlyto Lilly and our partners,but throughout the pharmaceutical industry.They are more than novel,though.They are revolutionaryand t
27、hey are changing how science is done.Partnerships can be risky as wellbut risk is at the heart of all great discoveries.In a sense,Lillyhas placed our success in our partners labs.Our partners have done the same.As a result,eachhas a vested interest in seeing the other become successful.The partners
28、hips provide many intangible benefits as well.In addition to scientific knowledgeexchange,we bring our best practices to the lab bench.We exchange ideasand come up with newonesabout how to do things better,faster and more productively.Below are two partnerships that we believe are revolutionizing th
29、e way we discover.Multiple sclerosis is adisease with significantunmet patient needs.Dirucotide has shownpotential in slowing theprogression of secondaryprogressive MS,and thusmay provide an effectivetherapeutic option forpatients with this debilitating disease.”Moving Outside Lilly Core AreasWith s
30、hared interest and experience in the neuro-science field,Lilly and Canadas BioMS Medical Corp.entered a licensing and development agreement for alarge molecule multiple sclerosis compound that,ifsuccessful,promises to be a novel treatment approach.The compound is in two pivotal phase III clinical tr
31、ialsfor secondary progressive MS as well as a phase IIclinical trial for relapsing-remitting MS.The benefit for BioMS:Lillys strong biotech experience Assistance in developing,launching,and marketing noveltherapeutic approaches Mutually-shared commitment to find a breakthrough medicine for MS patien
32、ts The benefit for Lilly:Opportunity to expand neuroscience franchise in area out-side Lillys core focus BioMSs deep expertise with molecule and disease state Compound is aligned with Lillys first-in-class or best-in-class approachTargeting Advances In Cancer TherapyLilly and Kyowa Hakko Kogyo Co.,L
33、td.,based inTokyo,Japan,have formed an alliance to bring tomarket Kyowas targeted cancer therapy,an inhibitorof the mitotic kinesin Eg5.Lilly has an exclusivelicense to develop and sell the compound worldwideexcept in Japan,and the companies will share rights in certain Asian countries.The benefit t
34、o Kyowa:Increased value of preclinical Eg5 program for shareholdersand cancer patients Partner with oncology experience and capabilities to expedite developmentThe benefit to Lilly:Opportunity to expand preclinical pipeline and support growing oncology franchise Access to a preclinical program that
35、may target various cancers Ability to leverage oncology capabilities and expertiseLilly is excited to workwith Kyowa Hakko todevelop an inhibitor of Eg5,an interesting new targetin cancer.Kyowa Hakko isa valued partner with a highquality R&D organization.This collaborative projectallows us to jointl
36、y expandour oncology R&D efforts.We look forward toadvancing this program inthe clinic to provide a newtreatment option to thosewho suffer from cancer.Kerry L.Blanchard,Ph.D.,M.D.Chief Operating Officer,Discovery ResearchEli Lilly and CompanyLillys PipelineWilliam W.Chin,M.D.Vice President,Discovery Research and Clinical InvestigationEli Lilly and Company